Gilead executive sells 3,000 shares in planned trade

Gilead Sciences, Inc. executive Johanna Mercier, Chief Commercial & Corporate Affairs Officer, sold 3,000 shares of common stock at $140.96 per share in an open-market transaction.

Rhea-AI Filing Summary

Gilead Sciences, Inc. executive Johanna Mercier, Chief Commercial & Corporate Affairs Officer, sold 3,000 shares of common stock at $140.96 per share in an open-market transaction. After this sale, she directly holds 128,779 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2025, indicating the timing was set in advance.

Insights

Equity compensation and insider-trading analyst

Small, pre-planned sale by a Gilead executive looks routine.

The filing shows Chief Commercial & Corporate Affairs Officer Johanna Mercier sold 3,000 shares of Gilead Sciences common stock at $140.96 per share. Following the trade, she still directly owns 128,779 shares, indicating this is a relatively small portion of her stake.

A key detail is that the transaction occurred under a Rule 10b5-1 trading plan adopted on February 20, 2025. Such plans are set up in advance, so the sale’s timing is pre-scheduled rather than opportunistic. Based on the size and context, this appears to be a routine liquidity event rather than a thesis-changing move.

Insider Trade Summary 10b5-1

Net Seller: 3,000 shares

Net Sell 1 txn

Insider Mercier Johanna

Role Chief Comm & Corp Aff Officer

Sold 3,000 shs ($423K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,000	$140.96	$423K

Holdings After Transaction: Common Stock — 128,779 shares (Direct)

Footnotes (1)

1. F1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

Key Figures

Shares sold: 3,000 shares Sale price per share: $140.96 per share Shares held after transaction: 128,779 shares +1 more

4 metrics

Shares sold 3,000 shares Open-market sale of Gilead common stock

Sale price per share $140.96 per share Price for the 3,000 Gilead shares sold

Shares held after transaction 128,779 shares Direct ownership after the reported sale

Trading plan adoption date February 20, 2025 Adoption date of Rule 10b5-1 plan governing this sale

Key Terms

Rule 10b5-1 trading plan, open-market sale, Form 4

3 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Johanna Mercier do in this Gilead (GILD) Form 4 filing?

Johanna Mercier reported selling 3,000 shares of Gilead common stock. The sale was an open-market transaction at $140.96 per share, and it was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2025.

How many Gilead (GILD) shares does Johanna Mercier hold after the reported sale?

After the reported transaction, Johanna Mercier directly owns 128,779 shares of Gilead common stock. This context shows that the 3,000 shares sold represent only a small portion of her overall direct holdings in the company.

Was the Gilead (GILD) insider sale by Johanna Mercier pre-planned?

Yes. The filing states that the transaction was made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. Such plans schedule trades in advance, reducing the significance of trade timing as an indicator of insider sentiment.

At what price did Johanna Mercier sell her Gilead (GILD) shares?

Johanna Mercier sold 3,000 shares of Gilead common stock at an average price of $140.96 per share. This price reflects the consideration she received per share in the reported open-market transaction disclosed in the Form 4.

Does this Gilead (GILD) Form 4 filing indicate any option exercises or derivative transactions?

No derivative transactions are listed in this Form 4. The filing shows only a non-derivative open-market sale of 3,000 shares of common stock, and the derivativeSummary section is empty, indicating no options or similar instruments were exercised in this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/16/2026 - 06:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mercier Johanna

(Last) (First) (Middle)

GILEAD SCIENCES, INC.

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CALIFORNIA 94404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Comm & Corp Aff Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/15/2026		S(1)		3,000	D	$140.96	128,779	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

Remarks:

	/s/ Amy Kim by Power of Attorney for Johanna Mercier	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)